1. Published

   Economic impact of poor compliance with pharmaceuticals.

   Hughes, D. & Hughes, D. A., 1 Aug 2002, In: Expert Review of Pharmacoeconomics and Outcomes Research. 2, 4, p. 327-335

   Research output: Contribution to journal › Article › peer-review

2. Published

   Impact of the abolition of the prescription charge in Wales.

   Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Jan 2009, p. O41.

   Research output: Contribution to conference › Paper

3. Published

   Pharmacokinetic-Pharmacodynamic modelling of Lapdap (CPG-DDS) combination.

   Hughes, D., Hughes, D. A., Watkins, B. & Winstanley, P., 1 Jan 2001, 2001 ed. Unknown.

   Research output: Book/Report › Commissioned report

4. Published

   Public meetings of the NICE appraisals committee

   Hughes, D. & Hughes, D. A., 1 Dec 2007.

   Research output: Contribution to conference › Paper

5. Published

   Pharmacoeconomic models that incorporate non-compliance

   Hughes, D. & Hughes, D. A., 1 Jul 2004.

   Research output: Contribution to conference › Paper

6. Published

   All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

   Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

   Research output: Book/Report › Commissioned report

7. Published

   Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments - piloting a discrete choice experiment

   Hughes, D., Myles, S., Hughes, D. A., Longo, M. & Lisles, C., 1 Jun 2006.

   Research output: Contribution to conference › Paper

8. Published

   Ultra-long acting pharmaceuticals: Do they result in better outcomes, and at an acceptable cost?

   Hughes, D. & Hughes, D. A., 1 Nov 2006.

   Research output: Contribution to conference › Paper

9. Published

   Quantitative risk-benefit analysis

   Hughes, D. & Hughes, D. A., 1 May 2007.

   Research output: Contribution to conference › Paper

10. Published

    The pharmacokinetic profile of Warfarn: a systematic review

    Hughes, D., Al-Zubiedi S.*, [. V., Hughes D.A., [. V. & Pirmohamed, M., 1 Dec 2007.

    Research output: Contribution to conference › Paper

11. Published

    Warfarin pharmacogenetics: Economic considerations.

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Jan 2007, In: Pharmacoeconomics. 25, 11, p. 899-902

    Research output: Contribution to journal › Article › peer-review

12. Published

    Use of PK-PD modelling to predict the impact of non-compliance

    Hughes, D. & Hughes, D. A., 1 Nov 2003.

    Research output: Contribution to conference › Paper

13. Published

    Development of an economic model to evaluate the cost-effectiveness of rival therapies for treating Crohn’s disease.

    Hughes, D., Kikuchi, T., Bodger, K. & Hughes, D. A., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

14. Published

    Multiple imputation of multiple multi-item scales when a full imputation model is infeasible

    Hughes, D., Plumpton, C. O., Morris, T., Hughes, D. A. & White, I. R., 26 Jan 2016, In: BMC Research Notes. 9, 45, p. 1-15

    Research output: Contribution to journal › Article › peer-review

15. Published

    Improving Outcomes in Children and Young People with Cancer: Analysis of the Potential Economic Impact of the Guidance.

    Hughes, D., Linck, P., Tunnage, B., Hughes, D. A. & Edwards, R. T., 1 Jan 2005, 2005 ed. Unknown.

    Research output: Book/Report › Commissioned report

16. Published

    Current assessment of risk-benefit by regulators: is it time to introduce decision analyses?

    Hughes, D., Hughes, D. A., Bayoumi, A. M. & Pirmohamed, M., 1 Aug 2007, In: Clinical Pharmacology and Therapeutics. 82, 2, p. 123-127

    Research output: Contribution to journal › Article › peer-review

17. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

18. Published

    Eliciting patients' preferences using a discrete choice experiment questionnaire: the role played by qualitative data in questionnaire design

    Hughes, D., Longo, M., Hughes, D. A., Myles, S. & Lisles, C., 1 Mar 2006.

    Research output: Contribution to conference › Paper

19. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Clofarabine (Evoltra)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

20. Published

    The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies.

    Hughes, D. & Hughes, D. A., 1 Jan 2001, 2001 ed. Unknown.

    Research output: Book/Report › Commissioned report

21. Published

    Drugs for exceptionally rare diseases: do they deserve special status for funding?

    Hughes, D., Tunnage, B. & Yeo, S. T., 1 Nov 2005, In: QJM - An International Journal of Medicine. 98, 11, p. 829-836

    Research output: Contribution to journal › Article › peer-review

22. Published

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Jan 2007, In: Value in Health. 10, 3, p. A109

    Research output: Contribution to journal › Article › peer-review

23. Published

    Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

    Hughes, D., Hughes, D. A., Vilar, F. J., Ward, C. C., Alfirevic, A., Park, B. K. & Pirmohamed, M., 1 Jun 2004, In: Pharmacogenetics. 14, 6, p. 335-342

    Research output: Contribution to journal › Article › peer-review

24. Published

    Methodological issues in the literature on costs of non-compliance in chronic diseases

    Hughes, D., Salas, M., Zuluaga, A., Hughes, D. A., Cowell, W., Lebmeie, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Nov 2008.

    Research output: Contribution to conference › Paper

25. Published

    Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

    Hughes, D., Pink, J., Lane, S., Pirmohamed, M. & Hughes D.A., [. V., 31 Oct 2011, In: British Medical Journal. 343, p. 1-14

    Research output: Contribution to journal › Article › peer-review

26. Published

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Nov 2003, In: Value in Health. 6, 6, p. 749

    Research output: Contribution to journal › Article › peer-review

27. Published

    Pharmacogenetic tests: the need for a level playing field

    Hughes, D., Pirmohamed, M. & Hughes, D. A., 1 Jan 2013, In: Nature Reviews Drug Discovery. 12, 3-4

    Research output: Contribution to journal › Article › peer-review

28. Published

    Drug compliance and pharmaceconomics

    Hughes, D. & Hughes, D. A., 1 Dec 2003.

    Research output: Contribution to conference › Paper

29. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Tenofovir disoproxil fumarate (Viread) for the treatment of hepatitis B.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

30. Published

    Economic evaluation during early (phase II) trials

    Hughes, D. & Hughes, D. A., 1 Nov 2002.

    Research output: Contribution to conference › Paper

31. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

32. Published

    A parenting programme for children at risk of developing conduct disorder: A cost-effectiveness analysis

    Hughes, D., Edwards, R. T., Ceilleachair, A., Bywater, T., Hughes, D. A. & Hutchings, J., 1 May 2007.

    Research output: Contribution to conference › Paper

33. Published

    Economic evaluations during early (Phase II) drug development: A role for clinical trial simulations.

    Hughes, D., Hughes, D. A. & Walley, T., 1 Jan 2001, In: Pharmacoeconomics. 19, 11, p. 1069-1077

    Research output: Contribution to journal › Article › peer-review

34. Published

    A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial)

    Hughes, D., Ramanan, A., Dick, A. D., Benton, D., Compeyrot-Lacassagne, S., Dawoud, D., Hardwick, B., Hickey, H., Hughes, D. A., Jones, A., Woo, P., Edelsten, C., Beresford, M. W. & The SYCAMORE Trail Management Group, [. V., 9 Jan 2014, In: Trials. 15, 14

    Research output: Contribution to journal › Article › peer-review

35. Published

    Abolition of prescription copayments in Wales: an observational study on dispensing rates.

    Hughes, D., Cohen, D., Alam, M. F., Dunstan, F. D., Myles, S., Hughes, D. A. & Routledge, P. A., 1 Aug 2010, In: Value in Health. 13, 5, p. 675-680

    Research output: Contribution to journal › Article › peer-review

36. Published

    Biosimilars: Evidential standards for health technology assessment.

    Hughes, D. & Hughes, D. A., 1 Jan 2009.

    Research output: Contribution to conference › Paper

37. Published

    Effects of the abolition of prescription charges in Wales: A preliminary analysis

    Hughes, D., Hughes, D. A., Alam, F., Cohen, D., Dunstan, F. & Routledge, P., 1 Apr 2008.

    Research output: Contribution to conference › Paper

38. Published

    Impact of the abolition of the prescription charge in Wales

    Hughes, D. & Hughes, D. A., 1 Nov 2008.

    Research output: Contribution to conference › Paper

39. Published

    The economics of evergreening.

    Hughes, D. & Hughes, D. A., 1 Jan 2009.

    Research output: Contribution to conference › Paper

40. Published

    Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations.

    Hughes, D., Hughes, D. A., Cowell, W., Koncz, T. & Cramer, J., 1 Nov 2007, In: Value in Health. 10, 6, p. 498-509

    Research output: Contribution to journal › Article › peer-review

41. Published

    All Wales Medicines Strategy Group Final Assessment Report – Agalsidase alfa (Replagal)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

42. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

43. Published

    A prototype agent-based model of antimalarial drug compliance

    Hughes, D., McKean, J., Rahlf, S., Shorter, H., Barnish, G., Paton, R., McBurney, P., Hughes, D. A. & Hastings, I., 1 Aug 2007.

    Research output: Contribution to conference › Paper

44. Published

    Back to basics: what is the relationship between dose and duration of drug action?

    Hughes, D. & Hughes, D. A., 1 May 2006.

    Research output: Contribution to conference › Paper

45. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Parathyroid hormone (Preotact)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

46. Published

    Mechanism-Based Approach to the Economic Evaluation of Pharmaceuticals: Pharmacokinetic/Pharmacodynamic/Pharmacoeconomic Analysis of Rituximab for Follicular Lymphoma.

    Hughes, D., Pink, J., Lane, S. & Hughes, D. A., 19 Mar 2012, In: Pharmacoeconomics.

    Research output: Contribution to journal › Article › peer-review

47. Published

    What determines which interventions improve compliance, and do they improve health outcomes in a cost-effective manner?

    Hughes, D., Hughes, D. A., LaFleur.*, [. V., Salas, M. & Shinogle, J., 1 May 2007.

    Research output: Contribution to conference › Paper

48. Published

    Is exercise effective in promoting mental well-being in older age? A systematic review.

    Hughes, D., Linck, P. G., Windle, G., Hughes, D. A., Linck, P., Russell, I. T. & Woods, R. T., 1 Aug 2010, In: Aging and Mental Health. 14, 6, p. 652-669

    Research output: Contribution to journal › Article › peer-review

49. Published

    Cost–effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs

    Hughes, D., Verhof, T. I., Redekop, W. K., van Schie, R. M., Bayat, S., Daly, A. K., Geitona, M., Haschke-Becher, E., Hughes, D. A., Kamali, F., Levin, L. A., Manolopoulos, V. G., Pirmohamed, M., Siebert, U., Stingl, J. C., Wadelius, M., de Boer, A. & Maitland-van der Zee, A. H., 1 Sept 2012, In: Pharmacogenomics. 13, 12, p. 1405-1417

    Research output: Contribution to journal › Article › peer-review

50. Published

    The problem of orphan drugs

    Hughes, D., Ferner, R. E. & Hughes, D. A., 16 Nov 2010, In: British Medical Journal. 341, p. 335-341

    Research output: Contribution to journal › Article › peer-review